BR0212141A - Inibidores de protease de cisteìna com estrutura 2-ciano-4-amino-pirimidina e atividade inibidora de catepsina k para o tratamento de inflamações e outras doenças - Google Patents

Inibidores de protease de cisteìna com estrutura 2-ciano-4-amino-pirimidina e atividade inibidora de catepsina k para o tratamento de inflamações e outras doenças

Info

Publication number
BR0212141A
BR0212141A BR0212141-7A BR0212141A BR0212141A BR 0212141 A BR0212141 A BR 0212141A BR 0212141 A BR0212141 A BR 0212141A BR 0212141 A BR0212141 A BR 0212141A
Authority
BR
Brazil
Prior art keywords
cathepsin
diseases
amino
treatment
inhibitory activity
Prior art date
Application number
BR0212141-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Eva Altmann
Kenji Hayakawa
Genji Iwasaki
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0121024A external-priority patent/GB0121024D0/en
Priority claimed from GBGB0121026.9A external-priority patent/GB0121026D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0212141A publication Critical patent/BR0212141A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR0212141-7A 2001-08-30 2002-08-29 Inibidores de protease de cisteìna com estrutura 2-ciano-4-amino-pirimidina e atividade inibidora de catepsina k para o tratamento de inflamações e outras doenças BR0212141A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0121024A GB0121024D0 (en) 2001-08-30 2001-08-30 Organic compounds
GBGB0121026.9A GB0121026D0 (en) 2001-08-30 2001-08-30 Organic compounds
PCT/EP2002/009661 WO2003020278A1 (en) 2001-08-30 2002-08-29 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases

Publications (1)

Publication Number Publication Date
BR0212141A true BR0212141A (pt) 2004-08-24

Family

ID=26246490

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212141-7A BR0212141A (pt) 2001-08-30 2002-08-29 Inibidores de protease de cisteìna com estrutura 2-ciano-4-amino-pirimidina e atividade inibidora de catepsina k para o tratamento de inflamações e outras doenças

Country Status (22)

Country Link
US (2) US7112589B2 (https=)
EP (1) EP1423121B1 (https=)
JP (1) JP4131701B2 (https=)
KR (1) KR100629834B1 (https=)
CN (1) CN1549717B (https=)
AR (1) AR036375A1 (https=)
AT (1) ATE345136T1 (https=)
AU (1) AU2002333758B2 (https=)
BR (1) BR0212141A (https=)
CA (1) CA2456127C (https=)
CO (1) CO5560576A2 (https=)
DE (1) DE60216122T2 (https=)
ES (1) ES2275946T3 (https=)
HU (1) HUP0401431A3 (https=)
IL (1) IL160295A0 (https=)
MX (1) MXPA04001930A (https=)
NZ (1) NZ531287A (https=)
PE (1) PE20030772A1 (https=)
PL (1) PL208280B1 (https=)
PT (1) PT1423121E (https=)
RU (1) RU2326119C2 (https=)
WO (1) WO2003020278A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201976D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0220187D0 (en) 2002-08-30 2002-10-09 Novartis Ag Organic compounds
CA2532948A1 (en) * 2003-07-21 2005-02-17 Novartis Ag Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
WO2005011703A1 (en) * 2003-08-04 2005-02-10 Akzo Nobel N.V. 2-cyano-1,3,5-triazine-4,6-diamine derivatives
EP1667983A4 (en) * 2003-09-23 2010-07-21 Merck Sharp & Dohme PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
CA2545723A1 (en) * 2003-11-19 2005-06-02 Novartis Ag Use of cathepsin k inhibitors in severe bone loss diseases
JPWO2005103012A1 (ja) * 2004-04-21 2008-03-13 小野薬品工業株式会社 ヒドラジノ複素環ニトリル化合物およびその用途
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
PE20060718A1 (es) * 2004-09-07 2006-10-04 Glaxo Group Ltd Compuestos 2-ciano pirimidinas sustitituidas como inhibidores de cisteina proteasas
WO2006040300A1 (en) * 2004-10-12 2006-04-20 N.V. Organon 4-cycloalkyl-pyrimidine-2-carbonitrile derivatives
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
GB0514684D0 (en) * 2005-07-18 2005-08-24 Novartis Ag Organic compounds
RU2424234C2 (ru) * 2005-08-05 2011-07-20 Ибриженикс Са Новые ингибиторы цистеиновых протеаз и их терапевтическое применение
TW200804352A (en) * 2005-09-02 2008-01-16 Glaxo Group Ltd Novel cysteine protease inhibitors
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
US7326715B2 (en) 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
CA2652600A1 (en) * 2006-05-22 2007-11-29 Velcura Therapeutics, Inc. Use of cathepsin k antagonists in bone production
JP2009541284A (ja) * 2006-06-23 2009-11-26 アストラゼネカ・アクチエボラーグ プテリジン誘導体およびカテプシン阻害剤としてのそれらの使用
EP1947091A1 (en) * 2007-01-16 2008-07-23 Glaxo Group Limited Pyrimidyl nitrile derivatives as cysteine protease inhibitors
US7932251B2 (en) 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
EP2222636B1 (en) 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
EP2240491B1 (en) 2008-01-09 2015-07-15 Amura Therapeutics Limited TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES
TW201035094A (en) 2009-01-16 2010-10-01 Organon Nv 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8026236B2 (en) 2009-01-16 2011-09-27 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
EP2316820A1 (en) * 2009-10-28 2011-05-04 Dompe S.p.A. 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them
WO2011086125A1 (en) 2010-01-15 2011-07-21 N.V. Organon 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES
EP3517630B1 (en) 2010-10-06 2022-01-19 Institució Catalana de Recerca i Estudis Avançats Method for the diagnosis, prognosis and treatment of breast cancer metastasis
US8524710B2 (en) * 2010-11-05 2013-09-03 Hoffmann-La Roche Inc. Pyrrolidine derivatives
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
EP3467124A1 (en) 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
KR101872965B1 (ko) 2012-10-12 2018-06-29 인바이오모션 에스.엘. Ｃ―ｍａｆ를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법
JP6577873B2 (ja) 2013-03-15 2019-09-18 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） がんの転移の予後診断および処置のための方法
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
TR201907389T4 (tr) 2013-10-09 2019-06-21 Fundacio Inst De Recerca Biomedica Irb Barcelona Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
AU2017271385B2 (en) 2016-05-25 2023-10-05 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
AU2018212618A1 (en) * 2017-01-27 2019-08-29 Genfit RORgamma modulators and uses thereof
CN108586356B (zh) * 2017-03-16 2021-02-19 杭州科巢生物科技有限公司 瑞博西尼新中间体及其制备瑞博西尼的合成方法
MX2020005182A (es) 2017-11-22 2020-08-17 Inbiomotion Sl Tratamiento terapeutico del cancer de mama basado en el estado del c-maf.
CN109467536B (zh) * 2018-12-23 2020-06-05 沧州普瑞东方科技有限公司 2-氯/羟基嘧啶-5-羧酸的合成方法
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
WO2020214834A1 (en) 2019-04-19 2020-10-22 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1251074B (de) 1960-11-02 1967-09-28 J R Geigy A -G , Basel (Schweiz) Selektives Herbizid
NL295648A (https=) * 1962-07-26
BR6915234D0 (pt) 1969-05-22 1973-06-07 American Cyanamid Co Novos derivados de melamina e processo para sua preparaca
CH627919A5 (de) * 1977-04-14 1982-02-15 Ciba Geigy Ag Herbizide mittel.
AU726522B2 (en) * 1995-09-01 2000-11-09 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US6313127B1 (en) 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
DE19817459A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
ES2199856T3 (es) * 1999-09-13 2004-03-01 Boehringer Ingelheim Pharmaceuticals, Inc. Nuevos compuestos heterociclicos, utiles como inhibidores reversibles de cisteina proteasas.
CN1374953A (zh) * 1999-09-16 2002-10-16 田边制药株式会社 含氮的6－员芳香环化合物
CN1657523A (zh) * 2000-04-28 2005-08-24 田边制药株式会社 环状化合物
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
SE0201976D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
EP1423121B1 (en) 2006-11-15
CA2456127A1 (en) 2003-03-13
PE20030772A1 (es) 2003-10-02
HUP0401431A3 (en) 2004-11-29
AR036375A1 (es) 2004-09-01
EP1423121A1 (en) 2004-06-02
WO2003020278A1 (en) 2003-03-13
CA2456127C (en) 2009-10-20
MXPA04001930A (es) 2004-06-15
PT1423121E (pt) 2007-02-28
CN1549717B (zh) 2011-08-17
ES2275946T3 (es) 2007-06-16
CN1549717A (zh) 2004-11-24
DE60216122D1 (de) 2006-12-28
HUP0401431A2 (hu) 2004-10-28
JP4131701B2 (ja) 2008-08-13
DE60216122T2 (de) 2007-09-06
JP2005505550A (ja) 2005-02-24
AU2002333758B2 (en) 2006-01-19
PL208280B1 (pl) 2011-04-29
NZ531287A (en) 2005-12-23
IL160295A0 (en) 2004-07-25
ATE345136T1 (de) 2006-12-15
RU2326119C2 (ru) 2008-06-10
KR100629834B1 (ko) 2006-09-29
RU2004109812A (ru) 2005-10-20
CO5560576A2 (es) 2005-09-30
US20040249153A1 (en) 2004-12-09
US7112589B2 (en) 2006-09-26
PL367821A1 (en) 2005-03-07
US20060074092A1 (en) 2006-04-06
KR20040029101A (ko) 2004-04-03

Similar Documents

Publication Publication Date Title
BR0212141A (pt) Inibidores de protease de cisteìna com estrutura 2-ciano-4-amino-pirimidina e atividade inibidora de catepsina k para o tratamento de inflamações e outras doenças
PT1423391E (pt) Pirrolopirimidinas como agentes para a inibicao de proteases de cisteina
ATE361300T1 (de) Derivate von heteroarylnitrilverbindungen
BR0316680A (pt) Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
BRPI0407919A (pt) pirrolopirimidinas espiro-substituìdas
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
BR9813197A (pt) Dipeptìdeo nitrilas
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
BRPI0410029B8 (pt) composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
ATE414526T1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
ATE438618T1 (de) Inhibitoren von humanem adam-10
BRPI0410663A (pt) compostos de hidroxiamidina e hidroxiguanidina como inibidores de uroquinase
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
SE0002739D0 (sv) New use
BR0309412A (pt) Indol-2-onas como inibidores seletivos da ciclooxigenase-2
BRPI0406618A (pt) Compostos possuindo atividade inibitória da propil oligopeptidase
BR0211847A (pt) Composto ou um derivado farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso do composto ou do derivado, métodos para tratar uma condição onde a inibição de trombina é requerida, e para tratar uma condição onde a terapia anticoagulante é indicada, e, processo para a preparação de um composto
EP1325918A4 (en) INHIBITORS OF CARDIAC MUSCLE CELL APOPTOSIS AND THERAPEUTIC / PROPHYLACTIC AGENTS AGAINST HEART DISEASE
ECSP044989A (es) Inhibidores de proteasa de cisteina con estructura de 2-ciano-4-amino-pirimidina y actividad inhibidora de catepsina k para el tratamiento de inflamaciones y otras enfermedades

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2269 DE 01/07/2014.